EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?

Giovana Paula Angelice, Pedro Henrique Roque iD, Gabriel Valente, Krishna Galvão, Livia Melo Villar iD, Vinicius Motta Mello iD, Francisco C A Mello, Bárbara Vieira Lago

Viruses · 2024

DOI: 10.3390/v16111710 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2024. Verfasst von Giovana Paula Angelice und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Viral Hepatitis, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil. Hauptthemen laut MEDLINE: Hepatitis B virus, RNA, Small Interfering, RNA Interference. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação Oswaldo Cruz, Ministério da Saúde, Brasil, Conselho Nacional de Desenvolvimento Científico, Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite an existing safe and effective vaccine for hepatitis B virus (HBV), it is still a major public health concern. Nowadays, several drugs are used to treat chronic hepatitis B; however, full healing remains controversial. The viral covalently closed circular DNA (cccDNA) formed by HBV forms a major challenge in its treatment, as does the ability of HBV to integrate itself into the host genome, which enables infection reactivation. Interfering RNA (RNAi) is a gene-silencing post-transcriptional mechanism which forms as a promising alternative to treat chronic hepatitis B. The aim of the present review is to assess the evolution of hepatitis B treatment approaches based on using RNA interference.

Methods

Data published between 2016 and 2023 in scientific databases (PubMed, PMC, LILACS, and Bireme) were assessed.

Results

In total, 76,949 articles were initially identified and quality-checked, and 226 eligible reports were analyzed in depth. The main genomic targets, delivery systems, and major HBV therapy innovations are discussed in this review. This review reinforces the therapeutic potential of RNAi and identifies the need for conducting further studies to fill the remaining gaps between bench and clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B virusRNA, Small InterferingRNA InterferenceHumansHepatitis BAntiviral AgentsAnimalsHepatitis B, ChronicGenetic Therapy

Stichwörter der Autor:innen

RNA interference (RNAi)chronic hepatitiscovalently closed circular DNA (cccDNA)gene therapyhepatitis B virus (HBV)

Substanzen

RNA, Small InterferingAntiviral Agents

Autor:innen und Institutionen

  • Laboratory of Viral Hepatitis, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.

ORCID-Profile: Pedro Henrique Roque, Livia Melo Villar, Vinicius Motta Mello

Förderung

  • Fundação Oswaldo Cruz, Ministério da Saúde, Brasil
  • Conselho Nacional de Desenvolvimento Científico
  • Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro

Zitieren

APA

Angelice, G. P., Roque, P. H., Valente, G., Galvão, K., Villar, L. M., Mello, V. M., Mello, F. C. A., & Lago, B. V. (2024). Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?. Viruses. https://doi.org/10.3390/v16111710

Vancouver

Angelice GP, Roque PH, Valente G, Galvão K, Villar LM, Mello VM, et al. Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?. Viruses. 2024. doi:10.3390/v16111710

BibTeX
@article{Angelice2024,
  author = {Angelice, Giovana Paula and Roque, Pedro Henrique and Valente, Gabriel and Galvão, Krishna and Villar, Livia Melo and Mello, Vinicius Motta and Mello, Francisco C A and Lago, Bárbara Vieira},
  title = {Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16111710}
}
Kostenlos starten →